T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction

References

• Horna P, Sotomayor EM. Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets. 2007;7(1):41–17. doi:10.2174/156800907780006940.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. Immunology beats cancer: a blueprint for successful translation. Nat Immunol. 2012;13(12):1129–1132. doi:10.1038/ni.2392.
   PubMed Web of Science ®Google Scholar
• Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res. 2004;92:13–27.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172.
   PubMed Web of Science ®Google Scholar
• Henick BS, Herbst RS, Goldberg SB. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opin Ther Targets. 2014;18(12):1407–1420. doi:10.1517/14728222.2014.955794.
   PubMed Web of Science ®Google Scholar
• Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3–4):643–671. doi:10.1007/s10555-013-9444-6.
   PubMed Web of Science ®Google Scholar
• Obrink B. CEA adhesion molecules: multifunctional proteins with signal-regulatory properties. Curr Opin Cell Biol. 1997;9(5):616–626. doi:10.1016/S0955-0674(97)80114-7.
   PubMed Web of Science ®Google Scholar
• Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol. 2006;18(5):565–571. doi:10.1016/j.ceb.2006.08.008.
   PubMed Web of Science ®Google Scholar
• Gur C, Maalouf N, Gerhard M, Singer BB, Emgard J, Temper V, Neuman T, Mandelboim O, Bachrach G. The Helicobacter pylori HopQ outermembrane protein inhibits immune cell activities. Oncoimmunology. 2019;8(4):e1553487. doi:10.1080/2162402X.2018.1553487.
   PubMed Web of Science ®Google Scholar
• Gur C, Maalouf N, Shhadeh A, Berhani O, Singer BB, Bachrach G, Mandelboim O. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1. Oncoimmunology. 2019;8(6):e1581531. doi:10.1080/2162402X.2019.1581531.
   PubMed Web of Science ®Google Scholar
• Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol. 2006;6(6):433–446. doi:10.1038/nri1864.
   PubMed Web of Science ®Google Scholar
• Kammerer R, Hahn S, Singer BB, Luo JS, Von Kleist S, Von Kleist S. Biliary glycoprotein (CD66a), a cell adhesion molecule of the immunoglobulin superfamily, on human lymphocytes: structure, expression and involvement in T cell activation. Eur J Immunol. 1998;28(11):3664–3674. doi:10.1002/(SICI)1521-4141(199811)28:11<3664::AID-IMMU3664>3.0.CO;2-D.
   PubMed Web of Science ®Google Scholar
• Singer BB, Scheffrahn I, Heymann R, Sigmundsson K, Kammerer R, Obrink B. Carcinoembryonic antigen-related cell adhesion molecule 1 expression and signaling in human, mouse, and rat leukocytes: evidence for replacement of the short cytoplasmic domain isoform by glycosylphosphatidylinositol-linked proteins in human leukocytes. J Immunol. 2002;168(10):5139–5146. doi:10.4049/jimmunol.168.10.5139.
   PubMed Web of Science ®Google Scholar
• Witzens-Harig M, Hose D, Junger S, Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H, Brackertz B, Rème T, et al. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Blood. 2013;121(22):4493–4503. doi:10.1182/blood-2012-05-429415.
   PubMed Web of Science ®Google Scholar
• Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer. 2007;7(1):2. doi:10.1186/1471-2407-7-2.
   PubMedGoogle Scholar
• Deng X, Liu P, Zhao Y, Wang Q Expression profiling of CEACAM6 associated with the tumorigenesis and progression in gastric adenocarcinoma. Genet Mol Res. 2014;13(3):7686–7697. doi:10.4238/2014.September.26.6.
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Matros E, Clancy T, Bailey G, Doff M, Zinner MJ, Ashley SW, Maitra A, Redston M, Whang EE, et al. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann Surg. 2005;241(3):491–496. doi:10.1097/01.sla.0000154455.86404.e9.
   PubMed Web of Science ®Google Scholar
• Jantscheff P, Terracciano L, Lowy A, Glatz-Krieger K, Grunert F, Micheel B, Brümmer J, Laffer U, Metzger U, Herrmann R, et al. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic signi ficance. J Clin Oncol. 2003;21(19):3638–3646. doi:10.1200/JCO.2003.55.135.
   PubMed Web of Science ®Google Scholar
• Strickland LA, Ross J, Williams S, Ross S, Romero M, Spencer S, Erickson R, Sutcliffe J, Verbeke C, Polakis P, et al. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol. 2009;218(3):380–390. doi:10.1002/path.2545.
   PubMed Web of Science ®Google Scholar
• Kim KS, Kim JT, Lee SJ, Kang MA, Choe IS, Kang YH, Kim S-Y, Yeom YI, Lee Y-H, Kim JH, et al. Overexpression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in colorectal cancer. Clin Chim Acta. 2013;415:12–19. doi:10.1016/j.cca.2012.09.003.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Miki Y, Ebina M, Abe K, Mori K, Narumi S, Suzuki T, Sato I, Maemondo M, Endo C, et al. Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. Br J Cancer. 2012;107(10):1745–1753. doi:10.1038/bjc.2012.422.
   PubMed Web of Science ®Google Scholar
• Zang M, Hu L, Cao S, Fan Z, Pang L, Li J, Su L, Li C, Liu W, Gu Q, et al. Dual role of carcinoembryonic antigen-related cell adhesion molecule 6 expression in predicting the overall survival of gastric cancer patients. Sci Rep. 2017;7(1):10773. doi:10.1038/s41598-017-11482-9.
   PubMedGoogle Scholar
• Zang M, Zhang B, Zhang Y, Li J, Su L, Zhu Z, Gu Q, Liu B, Yan M. CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway. PLoS One. 2014;9(11):e112908. doi:10.1371/journal.pone.0112908.
   PubMed Web of Science ®Google Scholar
• Burtin P, Quan PC, Sabine MC Nonspecific cross reacting antigen as a marker for human polymorphs, macrophages and monocytes. Nature. 1975;255(5511):714–716. doi:10.1038/255714a0.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xia T, Jin C, Gu D, Yu J, Shi W, Zhang KE, Zhang L, Ye J, Li L, et al. FOXP3 and CEACAM6 expression and T cell infiltration in the occurrence and development of colon cancer. Oncol Lett. 2016;11(6):3693–3701. doi:10.3892/ol.2016.4439.
   PubMed Web of Science ®Google Scholar
• Kuroki M, Matsuo Y, Kinugasa T, Matsuoka Y Three different NCA species, CGM6/CD67, NCA-95, and NCA-90, are comprised in the major 90 to 100-kDa band of granulocyte NCA detectable upon SDS-polyacrylamide gel electrophoresis. Biochem Biophys Res Commun. 1992;182(2):501–506. doi:10.1016/0006-291X(92)91760-N.
   PubMed Web of Science ®Google Scholar
• Kolla V, Gonzales LW, Bailey NA, Wang P, Angampalli S, Godinez MH, Madesh M, Ballard PL Carcinoembryonic cell adhesion molecule 6 in human lung: regulated expression of a multifunctional type II cell protein. Am J Physiol Lung Cell Mol Physiol. 2009;296(6):L1019–30. doi:10.1152/ajplung.90596.2008.
   PubMed Web of Science ®Google Scholar
• Chan CH, Stanners CP Novel mouse model for carcinoembryonic antigen-based therapy. Mol Ther. 2004;9(6):775–785. doi:10.1016/j.ymthe.2004.03.009.
   PubMed Web of Science ®Google Scholar
• Scholzel S, Zimmermann W, Schwarzkopf G, Grunert F, Rogaczewski B, Thompson J Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol. 2000;156(2):595–605. doi:10.1016/S0002-9440(10)64764-5.
   PubMed Web of Science ®Google Scholar
• Kammerer R, Zimmermann W. Coevolution of activating and inhibitory receptors within mammalian carcinoembryonic antigen families. BMC Biol. 2010;8(1):12. doi:10.1186/1741-7007-8-12.
   PubMedGoogle Scholar
• Pavlopoulou A, Scorilas A A comprehensive phylogenetic and structural analysis of the carcinoembryonic antigen (CEA) gene family. Genome Biol Evol. 2014;6(6):1314–1326. doi:10.1093/gbe/evu103.
   PubMed Web of Science ®Google Scholar
• Daniel S, Nagel G, Johnson JP, Lobo FM, Hirn M, Jantscheff P, Kuroki, M, von Kleist, S, Grunert, F. Determination of the specificities of monoclonal antibodies recognizing members of the CEA family using a panel of transfectants. Int J Cancer. 1993;55(2):303–310. doi:10.1002/ijc.2910550222.
   PubMed Web of Science ®Google Scholar
• Jantscheff P, Nagel G, Thompson J, Kleist SV, Embleton MJ, Price MR, Grunert, F.A CD66a-specific, activation-dependent epitope detected by recombinant human single chain fragments (scFvs) on CHO transfectants and activated granulocytes. J Leukoc Biol. 1996;59(6):891–901. doi:10.1002/jlb.59.6.891.
   PubMed Web of Science ®Google Scholar
• Du X, Luka J, Stafford LJ, Semenuk M, Wang X-P, Kantor J, Bristol , AJ.Colon and pancreas cancer specific antigens and antibodies. Patent US20130189268. 2013.
   Google Scholar
• Fantini M, David JM, Saric O, Dubeykovskiy A, Cui Y, Mavroukakis SA, Bristol A, Annunziata CM, Tsang KY, Arlen PM, et al. Preclinical characterization of a novel monoclonal antibody NEO-201 for the treatment of human carcinomas. Front Immunol. 2018;8:1899. doi:10.3389/fimmu.2017.01899.
   PubMed Web of Science ®Google Scholar
• Zeligs K, Arlen PM, Tsang K, Hernandez L, Fantini M, Annunziata CM. Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies. Cancer Res. 2017; 77:3025.
   Web of Science ®Google Scholar
• Markel G inventor. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM). Patent WO2013054320. 2013.
   Google Scholar
• Brackertz B, Conrad H, Daniel J, Kast B, Kronig H, Busch DH, Adamski, J, Peschel, C, Bernhard, H.FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes. Blood Cancer J. 2011;1(3):e11. doi:10.1038/bcj.2011.12.
   PubMedGoogle Scholar
• Moosmann A. Gezielte Reaktivierung spezifischer zytotoxischer T-Zellen mit Epstein-Barr-Virus-Vektoren. Germany: Ludwig-Maximilians-University Munich; 2002.
   Google Scholar
• Kuroki M, Matsuo Y, Kinugasa T, Matsuoka Y Augmented expression and release of nonspecific cross-reacting antigens (NCAs), members of the CEA family, by human neutrophils during cell activation. J Leukoc Biol. 1992;52(5):551–557. doi:10.1002/jlb.52.5.551.
   PubMed Web of Science ®Google Scholar
• Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz, U, Hank, T, Ehrenberg, R, Volkmar, M, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5(12):e1240859. doi:10.1080/2162402X.2016.1240859.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, Kang, B, Liu, Z, Jin, L, Xing, R, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018;24(7):978–985. doi:10.1038/s41591-018-0045-3.
   PubMed Web of Science ®Google Scholar
• Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin J-R, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175(4):984–97 e24. doi:10.1016/j.cell.2018.09.006.
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen L, Qiao SW, Nagaishi T, Blumberg RS Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits proximal TCR signaling by targeting ZAP-70. J Immunol. 2008;180(9):6085–6093. doi:10.4049/jimmunol.180.9.6085.
   PubMed Web of Science ®Google Scholar
• Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, et al. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest. 2015;125(2):739–751. doi:10.1172/JCI74894.
   PubMed Web of Science ®Google Scholar
• Slevogt H, Zabel S, Opitz B, Hocke A, Eitel J, N’Guessan PD, Lucka L, Riesbeck K, Zimmermann W, Zweigner J, et al. CEACAM1 inhibits Toll-like receptor 2-triggered antibacterial responses of human pulmonary epithelial cells. Nat Immunol. 2008;9(11):1270–1278. doi:10.1038/ni.1661.
   PubMed Web of Science ®Google Scholar
• Khairnar V, Duhan V, Maney SK, Honke N, Shaabani N, Pandyra AA, Seifert M, Pozdeev V, Xu HC, Sharma P, et al. CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production. Nat Commun. 2015;6:6217. doi:10.1038/ncomms7217.
   PubMed Web of Science ®Google Scholar
• Xydia M, Rahbari R, Ruggiero E, Macaulay I, Tarabichi M, Lohmayer R, Wilkening S, Michels T, Brown D, Vanuytven S, et al. Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients. Nat Commun. 2021;12(1):1119. doi:10.1038/s41467-021-21297-y.
   PubMed Web of Science ®Google Scholar
• Ramani SR, Tom I, Lewin-Koh N, Wranik B, Depalatis L, Zhang J, Eaton D, Gonzalez LC A secreted protein microarray platform for extracellular protein interaction discovery. Anal Biochem. 2012;420(2):127–138. doi:10.1016/j.ab.2011.09.017.
   PubMed Web of Science ®Google Scholar
• Nagaishi T, Pao L, Lin SH, Iijima H, Kaser A, Qiao SW, Chen Z, Glickman J, Najjar SM, Nakajima A, et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity. 2006;25(5):769–781. doi:10.1016/j.immuni.2006.08.026.
   PubMed Web of Science ®Google Scholar
• Shapira R, Weber JS, Geva R, Sznol M, Kluger HM, Wong DJL, Liang BC A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies. Journal of Clinical Oncology. 2020;38(15suppl). doi:10.1200/JCO.2020.38.15_suppl.3094.
   Google Scholar
• De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E Humanized mice for the study of immuno-oncology. Trends Immunol. 2018;39(9):748–763. doi:10.1016/j.it.2018.07.001.
   PubMed Web of Science ®Google Scholar
• Stripecke R, Munz C, Schuringa JJ, Bissig KD, Soper B, Meeham T, Yao, L-C, Di Santo, JP, Brehm, M, Rodriguez, E, et al. Innovations, challenges, and minimal information for standardization of humanized mice. EMBO Mol Med. 2020;12(7):e8662. doi:10.15252/emmm.201708662.
   PubMed Web of Science ®Google Scholar